Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
  • Patent number: 11360092
    Abstract: The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 14, 2022
    Assignees: The Research Foundation for The State University of New York, KDx Diagnostics, Inc.
    Inventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Nam Kim
  • Patent number: 11359025
    Abstract: Provided herein are antibodies specific for Interleukin-1 receptor accessory protein (IL1-RAP).
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 14, 2022
    Assignee: Cantargia AB
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • Patent number: 11351234
    Abstract: An object of the present invention is to provide a vaccine that can simultaneously reduce A? deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-?, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 7, 2022
    Assignee: IMMUNOTHERAPY DEVELOPMENT INC.
    Inventor: Yoh Matsumoto
  • Patent number: 11344638
    Abstract: The invention provides a compound having the following structure: T-DOTA-R, wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: May 31, 2022
    Inventor: Robert Norman Taub
  • Patent number: 11339212
    Abstract: The present disclosure is based, in part, on the discovery of antibodies that selectively targets human ?-synuclein aggregates such as oligomers/protofibrils, such as BAN0805. BAN0805 has a lower tendency to bind to the undesired monomeric ?-synuclein target as compared to mouse monoclonal antibody mAb47.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: May 24, 2022
    Assignee: BioArctic AB
    Inventors: Eva Nordström, Jessica Sigvardson, Patrik Nygren
  • Patent number: 11339218
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 24, 2022
    Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.
    Inventors: Weizao Chen, Tao Fu, Zuoxiang Xiao
  • Patent number: 11332543
    Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: May 17, 2022
    Assignee: FREDAX AB
    Inventors: Amanda Thuy Tran, Anders Axelsson, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Sven-Erik Strand, Urpo Juhani Lamminmäki
  • Patent number: 11325984
    Abstract: The present invention relates to methods for separating target cells from non-target cells using immunorosettes and magnetic particles. The method involves contacting a sample containing target cells and secondary targets such as erythrocytes with an antibody composition which allows immunorosettes of the target cells and the secondary targets to form. The sample is subsequently contacted with a second antibody composition which allows the binding of magnetic particles to the formed immunorosettes and free secondary targets. The immunorosettes and secondary targets labeled with magnetic particles are separated from non-target cells using a magnetic field. The antibody composition optionally contains bifunctional antibodies or tetrameric antibody complexes.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 10, 2022
    Assignee: StemCell Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 11319366
    Abstract: The present invention provides an antibody facilitating programmed necrosis of cells. The antibody can cause programmed necrosis of cells in the presence of tumor necrosis factor (TNF). Therefore, an inhibitor for the antibody can be used in the treatment of inflammatory diseases. Further, the present invention provides the application of the antibody facilitating programmed necrosis of cells in the inflammatory disease prognosis.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 3, 2022
    Assignee: SHANGHAI JW INFLINHIX CO., LTD.
    Inventors: Shisong Jiang, Wenshu Lu
  • Patent number: 11312784
    Abstract: Disclosed herein are multifunctional antigen-binding proteins comprising at least one multifunctional recombinant protein scaffold and at least one antigen-specific binding domain. Polynucleotides encoding the multifunctional antigen-binding proteins, vectors containing the disclosed polynucleotides, and cells that have been genetically engineered to express the polynucleotide are also provided. Methods of using the multifunctional antigen-binding proteins are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 26, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Hongtao Zhang, Zhiqiang Zhu, Lian Lam, Zheng Cai
  • Patent number: 11298433
    Abstract: Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a ?-emitter and ?-emitter.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 12, 2022
    Assignee: VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Tony Lahoutte, Matthias D'Huyvetter, Jens De Vos, Nick Devoogdt
  • Patent number: 11286302
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Patent number: 11279982
    Abstract: Provided herein is technology relating to detecting molecular markers relevant to cancer and particularly, but not exclusively, to methods and compositions for quantifying and/or detecting EGFR mRNA and/or EGFRvIII mRNA in biological samples.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: March 22, 2022
    Assignee: ABBOTT MOLECULAR INC.
    Inventors: Jeffrey D. Wuitschick, Kevin S. Nelson, Shihai Huang, Rupinder Kular, Carolyn Mullen, James Rhoads
  • Patent number: 11260131
    Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 preceptorson a cancer cell.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 1, 2022
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Xiaojuan Gong, Minoo J Moghaddam, Julian Alexander Barden
  • Patent number: 11246911
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 15, 2022
    Assignees: VIB VZW, Centre National de la Recherche Scientifique, Univeriteit Gent, Universite de Montpellier
    Inventors: Jan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
  • Patent number: 11248061
    Abstract: Provided herein are multivalent CD20-binding molecules, and compositions thereof, for use in selective killing of specific cell types and/or as therapeutics for the treatment of a variety of diseases, including cancer, tumors, and immune disorders. Certain multivalent CD20-binding molecules can be used to deliver agents into CD20-expressing cells, collecting diagnostic information, and/or monitoring the treatment of diseases, such as cancers, tumors, and immune disorders.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: February 15, 2022
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc
  • Patent number: 11248040
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 15, 2022
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
  • Patent number: 11242390
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Rebecca Croasdale-Wood, Christian Klein, Juergen Michael Schanzer, Kay-Gunnar Stubenrauch, Pablo Umana, Martina Geiger, Eric Sullivan, Jigar Patel
  • Patent number: 11207324
    Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 28, 2021
    Assignee: Seagen Inc.
    Inventors: Scott Peterson, Luke Walker
  • Patent number: 11202781
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 21, 2021
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Danielle Johnston Blackwell
  • Patent number: 11186641
    Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 30, 2021
    Assignee: OSLO UNIVERSITETSSYKEHUS HF
    Inventor: Anders Tveita
  • Patent number: 11186817
    Abstract: The present invention relates to an optimal medium for growing a cell line auxotrophic for tetrahydrofolate (THF) and producing a desired material in the cell with high efficiency. In particular, the present invention provides a method for enhancing cell growth by adding tetrahydrofolate (THF), or a precursor or derivative thereof into a chemical composition cell medium.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 30, 2021
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Hong-Woo Park, Bong Gyun Kim
  • Patent number: 11129904
    Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: September 28, 2021
    Assignee: Eisai R&D Managment Co., Ltd.
    Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
  • Patent number: 11116846
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: September 14, 2021
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Serengulam V. Govindan
  • Patent number: 11111525
    Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 7, 2021
    Assignees: Applied Biosystems, LLC, Agilent Technologies, Inc.
    Inventors: Kirsten Vang Nielsen, Jens Hyldig-Nielsen, Brett F. Williams
  • Patent number: 11066460
    Abstract: The present invention relates to vectors suitable for use in displaying proteins on the surface of bacteriophage M13 as fusion constructs with the surface protein P.III, bacteriophage M13 particles comprising a mutated P.III protein on the phage coat surface, as well as methods for producing bacteriophage M13 particles and methods for transfecting or infecting a host cell comprising the vectors and bacteriophage of the invention.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 20, 2021
    Assignee: Eli Lilly and Company
    Inventor: Sepideh Afshar
  • Patent number: 11058708
    Abstract: Galectin-3 is a pro-inflammatory molecule functioning as a cytokine hub, and also regulates unfolded protein responses (UPR) and ER stress. Thus, galectin-3 serves as a target for ameliorating inflammatory diseases such as allergic inflammation and diabetic inflammation and insulin resistance. RNA interference of endogenous galectin-3 expression, upregulates IL-12, IL-10 while downregulating IL-23 production, which offers protection against allergic inflammation. In addition, endogenous galectin-3 knockdown causes upregulation of XBP1, alleviating ER stress. Together, upregulated XBP1 and IL-10 offer protection against obesity-induced inflammation. Therefore, the embodiment of the invention resides in RNA interference of endogenous galectin-3 in appropriate cell types in order to rectify allergic and/or diabetic inflammation.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: July 13, 2021
    Inventor: Swey-Shen Chen
  • Patent number: 11046763
    Abstract: Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRP?.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: June 29, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Kipp Andrew Weiskopf, Julien Sage, Irving L. Weissman
  • Patent number: 11034775
    Abstract: The present disclosure involves biologically active proteins termed cysteine-optimized multimerizing stradomers. Thus, the present disclosure provides compositions and methods providing anti-autoimmune and anti-inflammatory activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 15, 2021
    Assignee: GLIKNIK INC.
    Inventors: Henrik Olsen, David S. Block
  • Patent number: 10994033
    Abstract: The invention relates to water soluble 18F-prosthetic groups and the synthesis and use 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 4, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: David Donnelly, David K. Leung
  • Patent number: 10987435
    Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 27, 2021
    Assignees: INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, NANOH
    Inventors: François Lux, Olivier Tillement, Maxime Saint Jean, Pierre Mowat, Pascal Perriat, Stéphane Roux, Anna Mignot
  • Patent number: 10981988
    Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 20, 2021
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventor: Timo Kars Van Den Berg
  • Patent number: 10968279
    Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Achal Pashine, Guodong Chen
  • Patent number: 10960037
    Abstract: A method of treating neurological condition in a subject by administration of a neuroprotective composition of a mixture of two or more triterpenes. Alzheimer's disease, Huntington's disease, stroke or Parkinson's disease are treated by administering a therapeutically effective amount of the neuroprotective composition to a subject.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 30, 2021
    Assignee: PHOENIX BIOTECHNOLOGY, INC.
    Inventors: Otis C. Addington, Robert A. Newman
  • Patent number: 10961308
    Abstract: Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of Embigin to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Assignees: THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: David T. Scadden, Lev Silberstein, Peter Kharchenko
  • Patent number: 10954305
    Abstract: The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 23, 2021
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 10953107
    Abstract: Described herein are methods and compositions related to compositions comprising combinations of V/K-type and V/E-type docking peptides and uses thereof, e.g., to deliver therapeutic agents to treat certain conditions such as cancer, infection, or trauma.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 23, 2021
    Assignee: Trustees of Boston University
    Inventors: Mark W. Grinstaff, Christopher Gromisch, Victoria Herrera, Nelson Ruiz-Opazo
  • Patent number: 10940204
    Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: March 9, 2021
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Lauren O. Bakaletz, Steven D. Goodman
  • Patent number: 10905752
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 2, 2021
    Assignee: VAXIMM AG
    Inventor: Heinz Lubenau
  • Patent number: 10894986
    Abstract: The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: January 19, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jun Luo, George Steven Bova, William Isaacs, Thomas Dunn, Rong Hu
  • Patent number: 10889651
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: January 12, 2021
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Patent number: 10874728
    Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: December 29, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Andrea Facciabene
  • Patent number: 10849986
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: December 1, 2020
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Serengulam V. Govindan
  • Patent number: 10780179
    Abstract: The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 22, 2020
    Assignee: IMMUNOBIOCHEM CORPORATION
    Inventor: Anton Neschadim
  • Patent number: 10765625
    Abstract: Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: September 8, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas Cox, Jennifer R. Cochran, Mark Smith, James R. Kintzing
  • Patent number: 10751284
    Abstract: Provided herein are tumor associated macrophage (TAM)-targeting liposome having a lipid bilayer; a targeting agent associated with the lipid bilayer, wherein the targeting agent comprises an antibody or fragment thereof that selectively binds a tumor associated macrophage; and a cytotoxic agent associated with the lipid bilayer, wherein the cytotoxic agent depletes tumor associated macrophages at or near the site of a tumor. Also provided are pharmaceutical compositions comprising the TAM-targeting liposomes and methods of treating a subject with cancer with the compositions.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: August 25, 2020
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Stephen Morton, Graziella Solinas
  • Patent number: 10745346
    Abstract: Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 18, 2020
    Inventors: Kuen-Feng Chen, Chung-Wai Shiau
  • Patent number: 10736975
    Abstract: A patient specific therapeutic composition provided in a single dose container, the total volume of which may be administered to a patient in a single treatment session. The composition includes a monoclonal antibody having a labeled fraction and an unlabeled fraction, and a pharmaceutically acceptable carrier. The label may be any of a radioisotope or a drug such as a chemotherapeutic or cytotoxic agent. The amount of the monoclonal antibody and any conjugated label molecule may depend on at least one patient specific parameter selected from a patient weight, a patient age, a patient height, a patient gender, a patient medical condition, and a patient medical history. Methods of administration, production, and articles of manufacture comprising the patient specific therapeutic composition are also disclosed.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 11, 2020
    Assignee: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik J. Dave, Yulian Zhang
  • Patent number: 10739349
    Abstract: The present invention provides, among other aspects, stabilized chromophoric nanoparticles. In certain embodiments, the chromophoric nanoparticles provided herein are rationally functionalized with a pre-determined number of functional groups. In certain embodiments, the stable chromophoric nanoparticles provided herein are modified with a low density of functional groups. In yet other embodiments, the chromophoric nanoparticles provided herein are conjugated to one or more molecules. Also provided herein are methods for making rationally functionalized chromophoric nanoparticles.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 11, 2020
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Daniel T. Chiu, Changfeng Wu, Xuanjun Zhang, Jiangbo Yu, Fangmao Ye
  • Patent number: RE48787
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 26, 2021
    Assignee: UCB Biopharma SRL
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage